Article
- The EMBO Journal (1997) 16, 7054 - 7066
- doi:10.1093/emboj/16.23.7054
BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C
Yutaka Kato1, Vladimir V. Kravchenko1, Richard I. Tapping1, Jiahuai Han1, Richard J. Ulevitch1 and Jiig-Dwan Lee1
- The Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037, USA
Correspondence to:
Jiig-Dwan Lee, E-mail: jdlee@scripps.edu
Received 23 June 1997; Revised 1 September 1997
Abstract
Big MAP kinase 1 (BMK1), also known as ERK5, is a mitogen-activated protein (MAP) kinase member whose biological role is largely undefined. We have shown previously that the activity of BMK1 in rat smooth muscle cells is up-regulated by oxidants. Here, we describe a constitutively active form of the MAP kinase kinase, MEK5(D), which selectively activates BMK1 but not other MAP kinases in vivo. Through utilization of MEK5(D), we have determined that a member of the MEF2 transcription factor family, MEF2C, is a protein substrate of BMK1. BMK1 dramatically enhances the transactivation activity of MEF2C by phosphorylating a serine residue at amino acid position 387 in this transcription factor. Serum is also a potent stimulator of BMK1-induced MEF2C phosphorylation, since a dominant-negative form of BMK1 specifically inhibits serum-induced activation of MEF2C. One consequence of MEF2C activation is increased transcription of the c-jun gene. Taken together, these results strongly suggest that in some cell types the MEK5/BMK1 MAP kinase signaling pathway regulates serum-induced early gene expression through the transcription factor MEF2C.
Keywords:
- BMK1,
- c-Jun,
- MAP kinase,
- MEF2C,
- MEK5



